Next, we briefly verified the effect of the CXCR4 antagonist AMD3100 on blocking signaling via the CXCL12/CXCR4 axis by assessing the proliferation, apoptosis and chemotaxis of AML cells with or without FLT3-ITD mutations. The gene discussed is CXCR4; the disease is acute myeloid leukemia.